

CORRECTION

Open Access

Correction to: Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy



Jia Wei^{1,2}, Ling Ma², Yi-Hui Lai³, Ruijie Zhang², Huameng Li⁴, Chenglong Li⁵ and Jiayuh Lin^{2*}

Correction to: *J Exp Clin Cancer Res*

<https://doi.org/10.1186/s13046-019-1072-8>

In the original publication of this article [1], there is an error in Fig. 4A.

The corrected Fig. 4A should be:

Author details

¹Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China. ²Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 108 N. Greene Street, Baltimore, MD 21201, USA. ³33 Linsen Road, Chungshan District, Taipei, Taiwan. ⁴Biophysics Graduate Program, The Ohio State University, Columbus, OH 43210, USA. ⁵College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.

Published online: 23 August 2019

Reference

1. Wei, et al. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy. *J Exp Clin Cancer Res.* 2019;38:63. <https://doi.org/10.1186/s13046-019-1072-8>.

* Correspondence: JLin@som.umaryland.edu

²Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 108 N. Greene Street, Baltimore, MD 21201, USA

Full list of author information is available at the end of the article



